Spyre Therapeutics Q2 EPS $(0.86) Beats $(0.95) Estimate
Portfolio Pulse from Benzinga Newsdesk
Spyre Therapeutics (NASDAQ:SYRE) reported a Q2 EPS loss of $(0.86), beating the analyst estimate of $(0.95) by 9.47%. This represents a significant improvement from the $(41.50) loss per share in the same period last year.
August 07, 2024 | 9:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Spyre Therapeutics reported a Q2 EPS loss of $(0.86), which is better than the analyst estimate of $(0.95). This marks a significant improvement from the $(41.50) loss per share in the same period last year.
The better-than-expected EPS loss indicates that Spyre Therapeutics is performing better than analysts anticipated, which is likely to have a positive short-term impact on the stock price. The significant improvement from last year's loss further strengthens this positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100